IV Antifungal Treatment for Thrush in NPO Patients with DKA

Immediate Management

The Infectious Diseases Society of America recommends switching the patient to IV fluconazole 100-200 mg daily, as this is the recommended systemic therapy for moderate to severe oropharyngeal candidiasis when oral administration is not feasible, with a duration of 7-14 days 1
Discontinue oral medications and initiate IV fluconazole at 100-200 mg daily for 7-14 days, as this represents the standard of care for moderate to severe oropharyngeal candidiasis when patients cannot take oral medications, with a strength of evidence based on clinical guidelines 1

The American College of Physicians and the Infectious Diseases Society of America suggest that fluconazole demonstrates 87-91% clinical cure rates for oropharyngeal candidiasis compared to 32-52% with nystatin, and IV administration achieves identical therapeutic levels as oral dosing, in patients with moderate to severe disease 2

The Infectious Diseases Society of America recommends considering alternative IV options, such as IV echinocandin, including caspofungin 70 mg loading dose, then 50 mg daily, or micafungin 100 mg daily, or anidulafungin 200 mg loading dose, then 100 mg daily, for patients who fail to respond to IV fluconazole after 7-14 days 1
The Infectious Diseases Society of America also recommends considering IV amphotericin B deoxycholate 0.3 mg/kg daily as a last resort due to toxicity, for patients with refractory disease 1

The American College of Clinical Pharmacy advises against continuing nystatin oral suspension in an NPO patient, as topical therapy requires direct mucosal contact and swallowing to be effective, making it completely ineffective when NPO, with a strength of evidence based on clinical guidelines 2
The American Heart Association recommends monitoring for drug interactions, such as the interaction between fluconazole and clopidogrel, which can reduce the antiplatelet effect of clopidogrel due to CYP2C19 inhibition, and considering alternative therapies such as IV echinocandin in patients taking clopidogrel 3
The American Diabetes Association recommends checking renal function closely, with serum creatinine monitored every 2-4 hours during DKA management, to adjust the dose of fluconazole accordingly, with a strength of evidence based on clinical guidelines 4, 5

The Infectious Diseases Society of America recommends transitioning back to oral fluconazole 100-200 mg daily to complete the full 7-14 day course once DKA resolves and the patient can tolerate oral intake, with a strength of evidence based on clinical guidelines 1
The American College of Physicians recommends monitoring for clinical response within 3-5 days, and obtaining fungal culture and susceptibility testing to rule out fluconazole-resistant species like Candida glabrata or Candida krusei if no improvement is seen, with a strength of evidence based on clinical guidelines 3